The Opium Withdrawal Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Opium Withdrawal Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Opium Withdrawal Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Opium Withdrawal Syndrome and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Opium Withdrawal Syndrome by 14 companies/universities/institutes. The top development phase for Opium Withdrawal Syndrome is preclinical with seven drugs in that stage. The Opium Withdrawal Syndrome pipeline has 14 drugs in development by companies and one by universities/ institutes. Some of the companies in the Opium Withdrawal Syndrome pipeline products market are: Sen-Jam Pharmaceutical, BioXcel Therapeutics and BDH Pharma.
The key targets in the Opium Withdrawal Syndrome pipeline products market include Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1), Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12), and Pannexin 1 (PANX1).
The key mechanisms of action in the Opium Withdrawal Syndrome pipeline product include Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1) Agonist with three drugs in Phase II. The Opium Withdrawal Syndrome pipeline products include five routes of administration with the top ROA being Oral and one key molecule types in the Opium Withdrawal Syndrome pipeline products market including Small Molecule.
Opium Withdrawal Syndrome overview
Opioid withdrawal syndrome is a life-threatening condition resulting from opioid dependence. Opioid withdrawal is a set of symptoms arising from the sudden withdrawal or reduction of opioids where previous usage has been heavy and prolonged. Signs and symptoms of withdrawal can include drug craving, anxiety, restless legs, nausea, vomiting, diarrhea, sweating, and an increased heart rate.
For a complete picture of Opium Withdrawal Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
